The annual general meeting held on 17 October 2012, has approved the acquisition of 100% of the shares of X-Pol by way of a capital increase against contribution in kind.
With the acquisition, former shareholders of X-Pol will hold 77.5% of Sygnis shares while the former Sygnis shareholders will be eligible for 22.5% shares of X-Pores.
German-based Sygnis Pharma focuses on research and development of new therapies to treat diseases of the central nervous system while X-Pol Biotech aims at the development of tools and technologies for the DNA amplification and sequencing market.